CYTEIR THERAPEUTICS
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
CYTEIR THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2012-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cyteir.com
Total Employee:
11+
Status:
Active
Contact:
312-953-3651
Email Addresses:
[email protected]
Total Funding:
156.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
7 Hills Pharma
7 Hills Pharma is developing novel immunotherapies for the treatment Of cancer.
Ankyra
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.
Avro
Avro Life Science is developing skin patches for generic drug delivery, focusing on therapeutics for children and the elderly.
Brise Pharma
Brise Pharma operates in the scientific research and technical service industry.
Cadence Health
Cadence, a pharma startup, aims to switch a birth control pill over-the-counter to create easy and affordable access to contraceptives.
CaroGen
CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
Cartesian Therapeutics
Pioneering Potent, Safer Cell Therapy in and Beyond Oncology
EIP Pharma
EIP Pharma Provides Healthcare Services.
EpiVario
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
F-Star Therapeutics
F-Star Therapeutics is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.
FTEX
FTEX Develops next-generation GaNFET based Electric Vehicle (EV) powertrains that extend the range and power of EVs by up to 30%.
HDT Bio
IMMUNE THERAPY FOR ALL: We’re transforming inventive immunotherapies for oncology and infectious disease.
HQS Quantum Simulations
HQS Quantum Simulations is developing quantum algorithms to predict molecular properties for specialty chemicals & pharmaceutical companies.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Innoviva
Innoviva is committed to building long-lasting value and improving patient care.
Intabio
Intabio is a developer of a real-time protein analytics platform used to transform the development of biotherapeutic drug.
JOINN Biologics
Your premier CDMO for biologics drug development and manufacturing, from early development, to IND, to commercial stage.
LB Pharmaceuticals
LB Pharmaceuticals specializes in developing a treatment for schizophrenia.
Mana Therapeutics
Next-Generation Immunotherapies
MyMeds&Me
My Meds & Me provides a web-based solution for the capture of adverse event, product complaint.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Nivagen Pharmaceuticals, Inc.
Nivagen engages in the development, acquisition, and sales of generic prescription drugs and over the counter products.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
PanCryos
PanCryos develops a next generation stem cell derived allogenic cell therapy or Type 1 diabetes.
Galectin Therapeutics
Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.
Recludix Pharma
Recludix pharma is a developing platform to treat cancer patients.
RUTI Immune
RUTI Immune developing a vaccine against Covid-19 and other known or unknown viruses.
Sisu Pharma
Sisu Pharma is developing drugs against a new target to treat prostate cancer.
T-knife
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Vibliome
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
XellSmart
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
CaaS Capital Management
CaaS Capital Management investment in Series C - Cyteir Therapeutics
Venrock
Venrock investment in Series C - Cyteir Therapeutics
Droia Ventures
Droia Ventures investment in Series C - Cyteir Therapeutics
Ample Plus Fund
Ample Plus Fund investment in Series C - Cyteir Therapeutics
Ally Bridge Group
Ally Bridge Group investment in Series C - Cyteir Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Series C - Cyteir Therapeutics
Avidity Partners
Avidity Partners investment in Series C - Cyteir Therapeutics
Acuta Capital Partners
Acuta Capital Partners investment in Series C - Cyteir Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Cyteir Therapeutics
Novo Holdings
Novo Holdings investment in Series C - Cyteir Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-03 | Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality |
Official Site Inspections
http://www.cyteir.com Semrush global rank: 5.15 M Semrush visits lastest month: 1.57 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cyteir Therapeutics"
Home - Cyteir
Cyteir Therapeutics ceased operations in 2024. Past press releases can be found here and past SEC filings can be found here. Inquiries should be directed to: [email protected] Download …See details»
Cancer’s Vulnerability Is Our Strength - Cyteir
Feb 10, 2021 CYTEIR THERAPEUTICS 128 Spring Street Building A, Suite 510 Lexington, MA 02421 +1 857-285-4140 cyteir.com CAREER AND CLINICAL CONTACT [email protected] …See details»
Cyteir Therapeutics - Crunchbase Company Profile & Funding
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its …See details»
Small molecules that selectively target RAD51 in cells defined by ...
128 Spring Street | Building A, Suite 510 | Lexington, MA 02421 | P: 857- 285-4140 | F: 857-285-4141 | www.cyteir.com . The company. Cyteir Therapeutics is a clinical stage VC- , funded, …See details»
Corporate Presentation 4Q2021
Cyteir History: Rapid Development from Discovery to Clinic. 4. 2015 • 2010-2012: Jackson Laboratory discovers the synthetic lethality of cytidine deaminase overexpression and HR …See details»
Cyteir Therapeutics - Funding, Financials, Valuation & Investors
Cyteir Therapeutics is registered under the ticker NASDAQ:CYT . Their stock opened with $18.00 in its Jun 17, 2021 IPO. Cyteir Therapeutics is funded by 14 investors. CaaS Capital …See details»
Cyteir Therapeutics - The Org
Through a unique cancer treatment approach, Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, …See details»
Cyteir Therapeutics - Contacts, Employees, Board Members
Organization. Cyteir Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Contacts 29. About. Cyteir Therapeutics has 8 current …See details»
Member Spotlight: Q&A with Cyteir Therapeutics - MassBio
Sep 1, 2022 He led Cyteir from start-up to public clinical stage company. He is a Board-certified medical oncologist with 25 years’ experience in cancer research from basic laboratory …See details»
Cyteir Therapeutics Secures $80 Million in Series C Financing to ...
LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today …See details»
Cyteir Therapeutics to Participate in the Morgan Stanley 20th …
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that …See details»
Cyteir Therapeutics Reports First Quarter 2022 ... - Business Wire
May 5, 2022 Cyteir expects to complete IND-enabling studies for CYT-1853 in the first half of 2022, and if the data supports an overall risk-benefit improvement and differentiation from CYT …See details»
Cyteir Therapeutics Reports Third Quarter 2021 Financial Results …
Nov 12, 2021 Cyteir completed the dose-escalation portion of its Phase 1/2 study of CYT-0851 up to the maximum feasible daily dose of 1200 mg and declared the maximum tolerated dose …See details»
Corporate Presentation 3Q2021
Cyteir History: Rapid Development from Discovery to Clinic. 4. 2015 • 2010-2012: Jackson Laboratory discovers the synthetic lethality of cytidine deaminase overexpression and HR …See details»
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 …
Mar 16, 2022 Cyteir completed the dose-escalation portion of the first-in-human Phase 1/2 trial of CYT-0851 up to the maximum feasible daily dose of 1200 mg and determined the maximum …See details»
Cyteir Therapeutics Selected to Join Russell 2000® Index
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a …See details»
Cyteir Therapeutics - Cyteir Therapeutics to Host Virtual Research …
Apr 26, 2022 Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will …See details»
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 …
Jul 7, 2020 Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team - Phase 1/2 study of first-in-class …See details»
Cyteir finally calls it quits after months of cost cutting - Fierce …
Jun 30, 2023 Cyteir established itself on the biotech scene in 2018 when it netted $29 million in series B funding and plucked Renschler to steer the ship after he led global hematology work …See details»
Cyteir: Although The Company Is Winding Down, The Lead Asset …
Sep 18, 2023 Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 inhibitor being …See details»